Ann: Increased Scheme Consideration from Pfizer, page-161

On the subject of the IER, we will get to see it. The report is for the benefit of shareholders. The company must distribute it with the Scheme Booklet. If the full report is too long and they choose to distribute a shortened version of the report, ResApp must ask the independent expert to prepare one: they cannot edit the full report to produce their own shortened version. Also, if they choose to distribute a shortened version the company is required to make the full report available free of charge.

However, I don't expect to see the Independent Expert's Report until after ASIC have approved the whole package.

This in turn means that we won't know exactly what our "right of reply" letter should say, although we can make some educated guesses in anticipation.